Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study - Wikidata - awgldk - TriplyDB

Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study

Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study

http://www.wikidata.org/entity/Q34538433

about

Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism.

P2860

Q37728330-D987576C-77AE-4E83-B6DA-CE23B8DD8872 Q38684913-9A22A1E0-46A3-4B3F-85A7-90C0B9432967

P2860

Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study

http://www.wikidata.org/entity/Q34538433

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targets for parathyroid hormon ...... spective incident cohort study

@ast

Targets for parathyroid hormon ...... spective incident cohort study

@en

Targets for parathyroid hormon ...... spective incident cohort study

@nl

type

label

Targets for parathyroid hormon ...... spective incident cohort study

@ast

Targets for parathyroid hormon ...... spective incident cohort study

@en

Targets for parathyroid hormon ...... spective incident cohort study

@nl

prefLabel

Targets for parathyroid hormon ...... spective incident cohort study

@ast

Targets for parathyroid hormon ...... spective incident cohort study

@en

Targets for parathyroid hormon ...... spective incident cohort study

@nl

P1433

Q34538433-B9C96B42-2086-4636-A86F-196C84937A36

P1476

Q34538433-1DF62355-0492-4E6C-8177-A698F8CFE42B

P2093

Q34538433-5041CEC3-53E2-4A42-AA42-7514F486A8B2

Q34538433-72E01371-56FC-470A-B2B4-744DB5063903

Q34538433-9E8246A3-B86C-4FEF-AC68-EC1E27EEEA06

Q34538433-B2D2E5AF-5FD1-4E8E-977E-C1A3EA912C6C

Q34538433-EF0F52E9-3107-4FC9-A095-6D3AB267FD36

Q34538433-F4B8BDFD-F6DA-4829-95FF-3D2849A3E945

Q34538433-F5E28B58-E6EE-4345-BA0B-D58AF72FA7BA

P2860

Q34538433-00FC56F7-FD4D-4F9D-8F61-6B2DA342377F

Q34538433-08BA314B-58B8-4F57-848D-E3A42689E88D

Q34538433-0DAB02FC-5B36-40B7-B36E-FA83CF3917F6

Q34538433-167329DC-442E-448B-A048-715EE189F447

Q34538433-19A09644-14B6-4A03-960D-BB05DFF365B2

Q34538433-2A76D053-8AA2-41CB-A99C-8C00FA34F627

Q34538433-2CACAB7D-D6D6-41DF-B496-CEE889581382

Q34538433-2FD175D7-FB53-4B8E-9513-70AE20F83D9B

Q34538433-397CA564-DEE0-4DA8-B7C8-FCADBE61B7D9

Q34538433-470FDFA1-6685-4634-ABE8-B4C7DD4FFCE7

P304

Q34538433-B7B33DF2-39A0-4A8A-A102-29527AA88E43

P31

Q34538433-9B059975-1127-4F2D-A510-1BD73A7C69FE

P356

Q34538433-2EEFA7DF-30B4-4D1A-B474-50F41DBEF248

P478

Q34538433-43E1AE7B-4A5B-4FFF-83BB-71177D0829D2

P577

Q34538433-F38B0223-1071-42A7-9A4C-BFAEE6111BE1

P5875

Q34538433-0EB68AA7-C58A-4080-A498-B48CACA36BA0

P698

Q34538433-43994A5E-8E93-4AC0-8AFF-F07D7B06D40F

P921

Q34538433-B63AF607-4E2B-449D-BBBB-68DDC5EA2106

P932

Q34538433-DE07DB4B-EA6D-4DAE-98D5-D665EB00F5EB

P356

1471-2369-15-132

P1433

P1476

Targets for parathyroid hormon ...... spective incident cohort study

@en

P2093

Carole Ayav

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Laurain

http://www.w3.org/2001/XMLSchema#string

Laurent Brunaud

http://www.w3.org/2001/XMLSchema#string

Luc Frimat

http://www.w3.org/2001/XMLSchema#string

Marie-Line Erpelding

http://www.w3.org/2001/XMLSchema#string

Michèle Kessler

http://www.w3.org/2001/XMLSchema#string

Serge Briançon

http://www.w3.org/2001/XMLSchema#string

P2860

PTH--a particularly tricky hormone: why measure it at all in kidney patients?

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease.

Ethics and observational studies in medical research: various rules in a common framework.

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.

Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Associations of frequency and duration of patient-doctor contact in hemodialysis facilities with mortality.

Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes.

Mineral and bone disease pattern in elderly haemodialysis patients.

P304

132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2369-15-132

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264833597

http://www.w3.org/2001/XMLSchema#string

P698

25123022

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

4236624

http://www.w3.org/2001/XMLSchema#string